Drug prices
lundi 11 octobre 2021 à 02:00Senator Menendez represents Big Pharma, and intends to torpedo plans to let Medicare negotiate drug prices. Other advanced countries have national medical systems which do negotiate in this way. In the US, the power of plutocracy has blocked this, and with Menendez's help, may block it again.
However, the underlying problem is the existence of patents that governments have bound themselves to respect even at the cost of people's lives.
The argument for medical patents would lose much of its apparent force if we took the tests for approval of medicines out of the hands of the drug manufacturers. That way of organizing them makes them susceptible to corruption. The funding for these tests should not have a direct interest in whether the drug is approved or not.